Read more

April 07, 2023
1 min read
Save

Top in allergy/asthma: Acute asthma exacerbations; atopic dermatitis treatment

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Age, type of asthma, previous ED admission and family history were all associated with an increased risk for hospital admission among children with acute asthma exacerbations, recent data show.

Armen Sanosyan, MD, PhD, of Washington University in St. Louis, said the “study justifies assessing these factors for modeling asthma inpatient admission in further studies.” It was the top story in allergy/asthma last week.

girl using asthma inhaler
Age, type of asthma, previous ED admission and family history were all associated with an increased risk for hospital admission among children with acute asthma exacerbations, recent data show. Image: Adobe Stock

Another top story covered a study that found the use of atopic dermatitis treatment may help prevent food allergy in infants, but it can also inhibit their growth.

Read these and more top stories in allergy/asthma below:

Multiple factors associated with hospital admission for pediatric patients with asthma

Multiple factors may predict whether pediatric patients will be admitted to the hospital for acute asthma exacerbations, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting. Read more.

Atopic dermatitis treatment reduces food allergy among infants, but inhibits growth

The use of topical corticosteroids to treat atopic dermatitis in infants also may help prevent hen’s egg allergy, but it may inhibit the baby’s growth as well, according to a study published in The Journal of Allergy & Clinical Immunology. Read more.

Dupilumab outperforms other biologics in asthma outcomes

Patients with asthma and specific eosinophil and IgE levels experienced greater improvements in exacerbations and FEV1 with dupilumab compared with other biologics, according to a study. Read more.

Remibrutinib exhibits long-term favorable safety profile for chronic spontaneous urticaria

Remibrutinib displayed sustained efficacy for chronic spontaneous urticaria with a favorable safety profile over 52 weeks, data show. Read more.

Students report lack of food allergy awareness on college campuses

Colleges and universities should take steps to improve food allergy awareness on campus, an expert said. Read more.